NCT07607535 SIRI Levels Following PENG Block in Pediatric Hip Surgery
| NCT ID | NCT07607535 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Poznan University of Medical Sciences |
| Condition | Hip Dysplasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-06-01 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective, randomized, double-blind clinical trial. Its aim is to evaluate whether adding a pericapsular nerve group (PENG) block to spinal anesthesia can reduce the inflammatory response after hip surgery in children. Hip surgery in children can cause a strong stress and inflammatory reaction, which may affect pain after surgery, the need for opioid medications, and recovery. Children aged 3 to 8 years will be randomly assigned to one of two groups: spinal anesthesia alone or spinal anesthesia combined with a PENG block. The main goal is to compare the Systemic Inflammation Response Index (SIRI), a blood-based marker of inflammation, between the two groups at 12 hours after surgery. Additional outcomes include other inflammatory markers, postoperative pain, opioid use, time to first rescue pain medication, and side effects.
Eligibility Criteria
Inclusion Criteria: * Age 3-8 years * Scheduled for elective unilateral hip surgery * American Society of Anesthesiologists (ASA) physical status I-III * Written informed consent from the parent or legal guardian Exclusion Criteria: * Contraindications to spinal anesthesia or PENG block * Infection at the planned needle insertion site * Coagulation disorders * Chronic immunosuppressive therapy or chronic steroid use * Active infection or inflammatory disease * Ongoing oncological treatment * Known allergy to local anesthetics or study-related medications * Conversion to general anesthesia * Refusal to participate
Contact & Investigator
Małgorzata Reysner, MD PhD
STUDY CHAIR
Poznań University of Medical Sciences
Frequently Asked Questions
Who can join the NCT07607535 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 8 Years, studying Hip Dysplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07607535 currently recruiting?
Yes, NCT07607535 is actively recruiting participants. Contact the research team at mreysner@ump.edu.pl for enrollment information.
Where is the NCT07607535 trial being conducted?
This trial is being conducted at Skórzewo, Poland.
Who is sponsoring the NCT07607535 clinical trial?
NCT07607535 is sponsored by Poznan University of Medical Sciences. The principal investigator is Małgorzata Reysner, MD PhD at Poznań University of Medical Sciences. The trial plans to enroll 100 participants.